Provided by Tiger Fintech (Singapore) Pte. Ltd.

VolitionRX

0.9200
+0.248837.07%
Post-market: 0.8299-0.0901-9.79%19:51 EDT
Volume:1.69M
Turnover:1.45M
Market Cap:94.78M
PE:-3.45
High:0.9388
Open:0.6700
Low:0.6600
Close:0.6712
Loading ...

VolitionRX Stockholders Approve Key Proposals at Meeting

TIPRANKS
·
Yesterday

VolitionRX Ltd. Conducted Annual Stockholders Meeting

Reuters
·
Yesterday

VolitionRX Ltd. President and CEO Cameron John Reynolds Acquires Common Shares

Reuters
·
16 Jun

BRIEF-Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure

Reuters
·
12 Jun

Volition Announces Mars Consortium Clinical Study Suggests Nu.q® H3.1. Concentrations Are Closely Associated With Sepsis and Organ Failure

THOMSON REUTERS
·
12 Jun

VolitionRx’s Strategic Positioning and Growth Potential Justifies Buy Rating

TIPRANKS
·
11 Jun

VolitionRX Initiated at Buy by Jones Trading

Dow Jones
·
10 Jun

VolitionRx initiated with a Buy at JonesResearch

TIPRANKS
·
10 Jun

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

THOMSON REUTERS
·
05 Jun

Director Innes Guy Archibald Reports Acquisition of VolitionRX Ltd. Common Shares

Reuters
·
04 Jun

Chief Scientific Officer Jacob Vincent Micallef Reports Acquisition of Common Shares in VolitionRX Ltd

Reuters
·
20 May

VolitionRX Ltd. CEO Cameron John Reynolds Reports Acquisition of Common Shares

Reuters
·
20 May

VolitionRX (VNRX) Receives a Hold from Benchmark Co.

TIPRANKS
·
19 May

VolitionRX Q1 EPS $(0.06) Up From $(0.10) YoY, Sales $246.38K Up From $171.53K YoY

Benzinga
·
16 May

VolitionRx Ltd. Reports 44% Increase in Q1 2025 Revenue, Reaches Commercial Milestone with Nu.Q® NETs Sales in Europe

Reuters
·
16 May

Press Release: VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

Dow Jones
·
12 May

BRIEF-VolitionRx Updates Progress Of Nu.Q NETs Test Adoption

Reuters
·
07 May

VolitionRX Limited: Outlines Broad Strategy to Become the 'Nets Company' Worldwide Through Licensing and Updates Progress of Nu.q® Nets Test Adoption

THOMSON REUTERS
·
07 May

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
30 Apr

BRIEF-VolitionRx Ltd May Offer & Sell Shares Of Common Stock Having Offering Price Of Up To $7.5 Mln - SEC Filing

Reuters
·
23 Apr